PD39-02 DOES RACE INFLUENCE THE SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA? - AN ANALYSIS OF 30,000 MEDICARE LIVES

Abstract

You have accessJournal of UrologyCME1 May 2022PD39-02 DOES RACE INFLUENCE THE SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA? - AN ANALYSIS OF 30,000 MEDICARE LIVES Gopal L. Narang, Sirikan Rojanasarot, Michael Murphy, Ben Cutone, and Mitchell R. Humphreys Gopal L. NarangGopal L. Narang More articles by this author , Sirikan RojanasarotSirikan Rojanasarot More articles by this author , Michael MurphyMichael Murphy More articles by this author , Ben CutoneBen Cutone More articles by this author , and Mitchell R. HumphreysMitchell R. Humphreys More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002597.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The prevalence of benign prostatic hyperplasia (BPH) is increasing globally. With a greater disease burden, effective but also equitable treatment is a priority. There is little data evaluating treatment disparities for patients with BPH, specifically when considering race. This study examines the association between race and rates of BPH surgical treatment among Medicare beneficiaries. METHODS: This real-world data analysis used 5% Medicare claims data to identify newly diagnosed men with BPH, age 66, between January 2010 and December 2018. Patients were followed until either their first BPH surgery, a diagnosis of prostate or bladder cancer, end of continuous Medicare enrollment, death, or end of the study period. Cox proportional hazards regression compared the likelihood of BPH surgery between men of different races, White vs. Black, Indigenous and People of Color (BIPOC), controlling for patients’ geographical region, Charlson Comorbidity Score, and baseline comorbidities. RESULTS: The study included 31,699 men with BPH; 13.7% were BIPOC. The median follow-up was 3.6 years (IQR 1.7-6.0) for White men and 2.8 years (IQR 1.3-5.2) for BIPOC men. At the end of the study period, BIPOC men had significantly lower BPH surgery rates than White patients (9.5% vs. 13.4%, respectively; p=0.02). In multivariable-adjusted Cox regression, BIPOC race was associated with a 19% lower likelihood of receiving BPH surgery than White race (HR, 0.81; 95% CI 0.70, 0.94). Among those who had surgery, transurethral resection of the prostate was the most common surgery for both White and BIPOC groups (49.4% vs. 56.8%, respectively; p=0.05). A higher proportion of BIPOC men underwent procedures in inpatient settings compared to White men (18.2% vs. 9.8%; p=0.00). CONCLUSIONS: Among a cohort of Medicare beneficiaries with BPH, there are notable treatment disparities when considering race. BIPOC men had lower rates of surgical treatment than White men with no difference in the type of procedure performed. BIPOC men were more likely to undergo procedures in inpatient settings. Improving patient access to BPH surgical procedures that can be performed in an outpatient setting may help address treatment disparities. Future research investigating treatment barriers and implications of site of service on access to care are needed. Source of Funding: Boston Scientific © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e652 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Gopal L. Narang More articles by this author Sirikan Rojanasarot More articles by this author Michael Murphy More articles by this author Ben Cutone More articles by this author Mitchell R. Humphreys More articles by this author Expand All Advertisement PDF DownloadLoading ...